{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:31:20Z","timestamp":1773210680651,"version":"3.50.1"},"reference-count":18,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Solid tumor research is undergoing a decisive transition: innovation is no longer simply \u201cfinding a new receptor\u201d or \u201cinhibiting a new enzyme\u201d, but integrating targets, biomarkers, and therapeutic modalities into strategies capable of anticipating tumor adaptation and therefore mechanisms of resistance [...]<\/jats:p>","DOI":"10.3390\/ijms27062520","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:43:31Z","timestamp":1773132211000},"page":"2520","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Issue \u201cNew Molecular Mechanisms and Advanced Therapies for Solid Tumors\u201d"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8972-7921","authenticated-orcid":false,"given":"Valentina","family":"De Falco","sequence":"first","affiliation":[{"name":"Institute of Endotypes in Oncology, Metabolism and Immunology \u201cGaetano Salvatore\u201d, Department of Biomedical Sciences, National Research Council (CNR), 80131 Naples, Italy"},{"name":"Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: Advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-Year Overall Survival with Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Alvarez-Vallina, L., and Sanz, L. (2026). Antiangiogenic therapies in cancer: From endogenous inhibitors to bispecific VEGF x PD (L)1 antibodies. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1736806"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"npj Biofilms Microbiomes"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100531","DOI":"10.1016\/j.jpi.2025.100531","article-title":"Digital pathology imaging artificial intelligence in cancer research and clinical trials: An NCI workshop report","volume":"20","author":"Makhlouf","year":"2026","journal-title":"J. Pathol. Inform."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_7","unstructured":"U.S. Food and Drug Administration (FDA) (2026, March 06). FDA Approves Zolbetuximab-Clzb with Chemotherapy for Gastric\/GEJ Adenocarcinoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma#:~:text=On%20October%2018%2C%202024%2C%20the,by%20an%20independent%20review%20committee."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Santos, N.J., Mosele, F.C., Barquilha, C.N., Barbosa, I.C., Lima, F.d.O., Barbosa, G.O., Carvalho, H.F., Delella, F.K., and Felisbino, S.L. (2025). SLIT\/ROBO Pathway and Prostate Cancer: Gene and Protein Expression and Their Prognostic Values. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115265"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sinicrope, F.A., Segovia, D., Sharma, N., Alberts, S.R., Hardin, A., Rich, T., and Shi, Q. (2026). Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147). J. Clin. Oncol., JCO2502086.","DOI":"10.1200\/JCO-25-02086"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","article-title":"FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti-PD-1-Based Immunotherapy","volume":"31","author":"Hu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41568-025-00864-1","article-title":"Decoding ferroptosis for cancer therapy","volume":"25","author":"Wahida","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41423-026-01387-x","article-title":"Tackling cuproptosis: From metabolic rewiring to therapeutic exploitation in cancer","volume":"23","author":"Hao","year":"2026","journal-title":"Cell. Mol. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ccell.2025.12.009","article-title":"Spatial omics at the forefront: Emerging technologies, analytical innovations, and clinical applications","volume":"44","author":"Liu","year":"2026","journal-title":"Cancer Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17588359251409047","article-title":"Current and future perspectives on radioligand therapy in advanced prostate cancer","volume":"18","author":"Ahmed","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s44276-025-00181-y","article-title":"Circulating tumour DNA assays in focus: Highlights from ASCO 2025 for clinicians","volume":"3","author":"Coakley","year":"2025","journal-title":"BJC Rep."},{"key":"ref_18","first-page":"202506","article-title":"Disulfidptosis and its emerging relevance in cancer and immunity","volume":"1","author":"Li","year":"2025","journal-title":"Ferroptosis Oxid. Stress"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2520\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:47:14Z","timestamp":1773132434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27062520"],"URL":"https:\/\/doi.org\/10.3390\/ijms27062520","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}